GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » EBITDA Margin %

Apures Co (XKRX:149300) EBITDA Margin % : -516.25% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Apures Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Apures Co's EBITDA for the six months ended in Dec. 2023 was ₩-3,401.7 Mil. Apures Co's Revenue for the six months ended in Dec. 2023 was ₩658.9 Mil. Therefore, Apures Co's EBITDA margin for the quarter that ended in Dec. 2023 was -516.25%.


Apures Co EBITDA Margin % Historical Data

The historical data trend for Apures Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apures Co EBITDA Margin % Chart

Apures Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,057.62 -2,291.96 -73.29 -443.26 -516.25

Apures Co Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,057.62 -2,291.96 -73.29 -443.26 -516.25

Competitive Comparison of Apures Co's EBITDA Margin %

For the Diagnostics & Research subindustry, Apures Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apures Co's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Apures Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Apures Co's EBITDA Margin % falls into.



Apures Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Apures Co's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-3401.663/658.916
=-516.25 %

Apures Co's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-3401.663/658.916
=-516.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apures Co  (XKRX:149300) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Apures Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Apures Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Apures Co (XKRX:149300) Business Description

Traded in Other Exchanges
N/A
Address
44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792
Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines